source
- Personalized mRNA melanoma vaccine shows clinical success, reviving optimism for the platformModerna and Merck reported positive results from a personalized mRNA vaccine designed to treat melanoma in a recent clinical study. The outcome is being hailed as a boost for mRNA technology, whic…
- BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readoutsBristol Myers Squibb, long recognized for its oncology work, is re‑investing in neurological and psychiatric disease programs, a move rooted in assets gained from its 2019 $74 billion Celgene merge…